Impacts of Glucose Forecasting

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Impacts of Estimated Future Glucose Values on Health

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04217369
• Other study ID #: 2019
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 4, 2020
• Est. completion date: December 1, 2020

Study information

• Verified date: January 2020
• Source: Bio Conscious Technologies Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study of individuals with type I or type II diabetes. It is meant to test the effect of using the Diabits app on a participant's blood glucose control. The Diabits app is a diabetes management app which integrates with your continuous glucose monitor (CGM) and presents not only your current blood glucose trend, but also an estimate of your blood glucose values up to 60 minutes into the future. The Diabits app has been available in the USA and Canada for the past two years and was validated for predictive accuracy at BC Children's Hospital in Canada in 2017 with a predicted accuracy of 94.9%. Diabits app users in North America have shown some improvements in their individual time in range (TIR) and HbA1c values. This study aims to validate those results in a clinical setting. The study will randomise a total of 90 participants into using the Diabits app with or without the glucose forecasting enabled to help determine if the glucose forecasting (or predictions) can help participants make better treatment decisions and improve not only measurements of glucose such as time in range and HbA1c, but also reduce anxiety and improve quality of life with diabetes.

Description:

This study focuses on the impact of the Diabits app, a smartphone application which assists a person with diabetes to better manage their blood glucose. The Diabits app connects to a user's continuous glucose monitor (CGM) such as an Abbott Freestyle Libre, and predicts what the user's blood glucose will be over the next 60 minutes, updating every 5 minutes. The Diabits app displays that prediction to the user so that the user may make proactive decisions about insulin and food, with the goal of achieving more stable blood glucose control.

The study will evaluate the impact which having access to blood glucose predictions has on a user's time in range (TIR). The hypothesis is that having access to blood glucose predictions will improve the user's ability to stay within their target blood glucose range by 5% within a given 24 hour period. This is a randomized controlled trial. A control group with Abbott Freestyle Libre CGMs will be recruited, and given a version of the Diabits app which does not display any blood glucose forecasts. A treatment group, also with Abbott Freestyle Libres, will be given the Diabits app with glucose forecasts enabled. Both groups will be asked to use the app as their primary diabetes management tool for the duration of the study.

The study will run for 3 months. At the beginning of the study the 90 participants will be separated evenly into two groups. A blood test will be done to measure HbA1c and each participant will complete a number of surveys. At the end of the study the same activities will occur. Following conclusion, results will be evaluated to determine what differences develop between the control and treatment groups.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: December 1, 2020
• Est. primary completion date: December 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• An individual with type I or type II diabetes treated with > 1 insulin injections

• Currently using a smartphone compatible with the Diabits app

• Are willing to, or already wear a CGM which is compatible with the Diabits app

• Willing and able to provide informed consent, to have their data collected, and to complete questionnaires that are included as part of the protocol.

• HbA1c between 7.5 - 10 % ( 86 - 58 mmol/mol)

Exclusion Criteria:

• Patients who are pregnant or are planning to become pregnant during the duration of the study.

• Patients with major psychiatric illness or severe end-stage diabetes complications.

• Patients who use sensor-augmented pumps with automated features such as hybrid closed loop or predictive insulin suspension. This includes those who use non-commercial software such as DIY closed loop.

• Patients with prior use of the Diabits app

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2

Intervention

Device:
• Diabits Predictions
Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bio Conscious Technologies Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time in Range	The proportion of time in a single day in which a given participant's blood glucose is within a predetermined target blood glucose range.	One day
Secondary	BGL variability (SD) BGL variability (SD)	The standard deviation from the mean of the participant's blood glucose	1 day
Secondary	BGL Variability (ADRR)	Average Daily Risk Range, a measure of variability which assesses two weeks of data to identify risk of out-of-range events.	14 days
Secondary	Time below range	A proportion of time where the participant's blood glucose is below 3.9 mmol/L, and is below 3.0 mmol/L, respectively	1 day
Secondary	Change is HbA1c	A calculated metric which is an analogue to a laboratory HbA1c measure, to assess the likelihood of measurable changes in HbA1c	14 days
Secondary	Laboratory HbA1c	A blood test which measures hemoglobin A1c, an indicator of long term tissue damage	90 days